Skip to main content

Table 5 Safety and Toleration: Number of adverse events and patients reporting events

From: Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial

Treatment Arm

A

B

C

Safety population size (N)

51

53

51

Total number of events

12

12

15

Patients reporting events (%)

7 (13.7)

7 (13.2)

10 (19.6)

Events causing eye discomfort

5

6

3

Patients reporting events causing eye discomfort (%)

3 (5.9)

2 (3.8)

2 (3.9)

Extra-ocular/systemic events

7

6

12

Patients reporting extra-ocular/systemic events (%)

6 (11.8)

4 (7.5)

10 (19.6)